Shattuck Labs, Inc. (NASDAQ:STTK) Q3 2022 Earnings Conference Call November 8, 2022 4:30 PM ET
Company Participants
Conor Richardson - Senior Director of Finance and Investor Relations
Taylor Schreiber - Chief Executive Officer
Lini Pandite - Chief Medical Officer
Andrew Neill - Chief Financial Officer
Conference Call Participants
Marc Frahm - Cowen
Gil Blum - Needham & Company
Carly Kenselaar - Citi
Kaveri Pohlman - BTIG
Zhiqiang Shu - Berenberg
Operator
Good afternoon, everyone, and welcome to Shattuck Labs Third Quarter 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode. Later we will conduct a question-and-answer session. [Operator Instructions] As a reminder, this conference is being recorded.
I will now turn the call over to your host, Conor Richardson, Senior Director of Finance and Investor Relations at Shattuck Labs. Conor, Please go ahead.
Conor Richardson
Thank you, operator. Good afternoon, everyone, and welcome to the Shattuck Labs conference call regarding our third quarter 2022 financial results and recent business updates. A press release reporting our financial results was issued after market close this afternoon and can be found on the Events & Presentations section of our website, shattucklabs.com.
During this afternoon's call, the Shattuck leadership team will provide a business overview of the third quarter of 2022, including clinical development updates from SL-172154, our lead program and SL-279252. We will refer to these as 154 and 252 throughout today's earnings call.
Speaking on today's call will be our Chief Executive Officer and Scientific Co-Founder, Dr. Taylor Schreiber, who will review our pipeline progress and upcoming key milestones; followed by our Chief Medical Officer, Dr. Lini Pandite, who will provide an update on our clinical activities and then our Chief Financial Officer, Andrew Neill, will review our third quarter 2022 financial results and financial guidance. We will then open the call for questions after Dr. Schreiber makes some closing remarks.
Before we begin, I would like to remind you that today's webcast contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements represent management's judgment as of today and may involve risks and uncertainties that could cause actual results to differ materially from those expressed in or implied by these statements.
For more information on these risks and uncertainties, please refer to our most recent Annual Report on Form 10-K for the year ended December 31, 2021, and our other filings with the SEC, which are available from the SEC's website or on our corporate website, shattucklabs.com. Any forward-looking statements represent our views as of today, November 8, 2022.